Patents Assigned to Synaptic Pharmaceutical Corporation
-
Patent number: 5885785Abstract: The present invention provides an isolated nucleic acid molecule encoding a 5-HT.sub.2 receptor, and an isolated protein which is a human 5-HT.sub.2 receptor. The invention also provides vectors comprising DNA molecules encoding a human 5-HT.sub.2 receptor, and vectors adapted for expression of the 5-HT.sub.2 receptor in bacterial, yeast, or mammalian cells. In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the 5-HT.sub.2 receptor, a method for determining whether a ligand which is not known to be capable of binding to the 5-HT.sub.2 receptor can bind to the 5-HT.sub.2 receptor, a method for detecting the presence of 5-HT.sub.2 receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT.sub.2 receptor. The invention herein also concerns an antibody directed to the human 5-HT.sub.2 receptor, such as a monoclonal antibody directed to an epitope of the 5-HT.sub.Type: GrantFiled: March 8, 1996Date of Patent: March 23, 1999Assignee: Synaptic Pharmaceutical CorporationInventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek
-
Patent number: 5882855Abstract: This invention provides isolated nucleic acid molecules encoding a human dopamine D.sub.1 receptor, isolated proteins which are human dopamine D.sub.1 receptor, vectors comprising isolated nucleic acid molecules encoding a human dopamine D.sub.1 receptor, mammalian cells comprising such vectors, antibodies directed to a human dopamine D.sub.1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human dopamine D.sub.1 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human dopamine D.sub.1 receptor, pharmaceutical compounds related to human dopamine D.sub.1 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant human dopamine D.sub.1 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving a human dopamine D.sub.1 receptor.Type: GrantFiled: October 5, 1993Date of Patent: March 16, 1999Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Paul R. Hartig
-
Patent number: 5866579Abstract: This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human .alpha..sub.2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the .alpha..sub.2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: April 11, 1997Date of Patent: February 2, 1999Assignee: Synaptic Pharmaceutical CorporationInventors: Wai C. Wong, Yoon T. Jeon, T. G. Murali Dhar, Charles Gluchowski
-
Patent number: 5861309Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.Type: GrantFiled: August 21, 1995Date of Patent: January 19, 1999Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Richard L. Weinshank, Carlos Forray
-
Patent number: 5786155Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptor, an isolated protein which is a human 5-HT.sub.1E receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1E receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1E receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1E receptor, pharmaceutical compounds related to human 5-HT.sub.1E receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1E receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1E receptor.Type: GrantFiled: October 12, 1995Date of Patent: July 28, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Patent number: 5780485Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.Type: GrantFiled: April 3, 1995Date of Patent: July 14, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
-
Patent number: 5766879Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, an isolated protein which is a mammalian 5-HT.sub.4 receptor, an isolated protein which is a human 5-HT.sub.4 receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4 receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4 receptor, pharmaceutical compounds related to the human 5-HT.sub.4 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4 receptor.Type: GrantFiled: July 31, 1995Date of Patent: June 16, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe Gerald, Paul R. Hartig, Theresa Branchek, Richard L. Weinshank
-
Patent number: 5766848Abstract: This invention provides an isolated nucleic acid molecules encoding mammalian betaine/GABA transporters, including a human betaine/GABA transporter. This invention further provides vectors comprising said isolated nucleic acid molecules, and mammalian cells comprising such vectors. This invention further provides isolated mammalian and human betaine/GABA transporter proteins and antibodies directed thereto. This invention provides nucleic acid molecule probes useful for detecting nucleic acid molecules encoding mammalian or human betaine/GABA transporters, antisense oligonucleotides complementary to any sequences of a nucleic acid molecules which encode a mammalian or human betaine/GABA transporter. This invention further provides pharmaceutical compounds related to mammalian and human betaine/GABA transporters, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human betaine/GABA transporter.Type: GrantFiled: August 16, 1994Date of Patent: June 16, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Laurence A. Borden, Kelli E. Smith, Richard L. Weinshank
-
Patent number: 5767131Abstract: The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: ##STR1## wherein Y is --(CH.sub.2).sub.n --, where n is 1, 2, 3, 4 or 5; --(CH.sub.2).sub.h --O--(CH.sub.2).sub.k --, where h and k are independently the same or different and are 2, 3 or 4; --(CH.sub.2).sub.h --CH.dbd.CH--(CH.sub.2).sub.k --; or --(CH.sub.2).sub.h --C.tbd.C--(CH.sub.2).sub.k --, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH.sub.2 ; wherein R.sup.1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R.sup.2 and R.sup.4 are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R.sup.3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R.sup.5 and R.sup.6 are independently the same or different and are H, OH, Cl, Br, F, NO.sub.2, CN, CF.Type: GrantFiled: February 23, 1996Date of Patent: June 16, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, John M. Wetzel, George Chiu, Mohammed R. Marzabadi, Wai C. Wong, Dhanapalan Nagarathnam
-
Patent number: 5756348Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammalian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human glycine transporter, pharmaceutical compounds reType: GrantFiled: November 10, 1994Date of Patent: May 26, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Laurence A. Borden, Theresa Branchek, Paul R. Hartig, Richard L. Weinshank
-
Patent number: 5714381Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor.Type: GrantFiled: June 6, 1995Date of Patent: February 3, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Carlos Forray, Richard L. Weinshank
-
Patent number: 5712148Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian betaine/GABA transporter, an isolated nucleic acid molecule encoding a human betaine/GABA transporter, an isolated protein which is a mammalian betaine/GABA transporter, an isolated protein which is a human betaine/GABA transporter, vectors comprising an isolated nucleic acid molecule encoding a mammalian betaine/GABA transporter, vectors comprising an isolated nucleic acid molecule encoding a human betaine/GABA transporter, mammalian cells comprising such vectors, antibodies directed to the mammalian betaine/GABA transporter and antibodies directed to the human betaine/GABA transporter, nucleic acid probes useful for detecting nucleic acid molecules encoding mammalian betaine/GABA transporters and human betaine/GABA transporters, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian betaine/GABA transporter or a human betaine/GABA transporter, pharmaceutical compounds relateType: GrantFiled: October 17, 1995Date of Patent: January 27, 1998Assignee: Synaptic Pharmaceutical CorporationInventors: Laurence A. Borden, Kelli E. Smith, Richard L. Weinshank
-
Patent number: 5677321Abstract: This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: February 29, 1996Date of Patent: October 14, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Yoon T. Jeon, Charles Gluchowski
-
Patent number: 5661024Abstract: The present invention provides an isolated nucleic acid molecule encoding an 5-HT.sub.2 receptor, and an isolated protein which is a human 5-HT.sub.2 receptor.The invention also provides vectors comprising DNA molecules encoding a human 5-HT.sub.2 receptor, and vectors adapted for expression of the 5-HT.sub.2 receptor in bacterial, yeast, or mammalian cells.In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the 5-HT.sub.2 receptor, a method for determining whether a ligand which is not known to be capable of binding to the 5-HT.sub.2 receptor can bind to the 5-HT.sub.2 receptor, a method for detecting the presence of 5-HT.sub.2 receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT.sub.2 receptor.The invention herein also concerns an antibody directed to the human 5-HT.sub.2 receptor, such as a monoclonal antibody directed to an epitope of the 5-HT.sub.Type: GrantFiled: November 30, 1994Date of Patent: August 26, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek
-
Patent number: 5658786Abstract: This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters and methods of isolating these nucleic acid molecules. Further provided are vectors comprising the nucleic acid molecules as well as mammalian cells comprising such vectors, and antibodies directed to the GABA and taurine transporters. Nucleic acid probes useful for detecting nucleic acid molecules encoding GABA and taurine transporters are also provided. Antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a GABA or taurine transporter are further provided. Pharmaceutical compounds related to GABA and taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding a normal or a mutant GABA or taurine transporter are also provided.Type: GrantFiled: December 19, 1994Date of Patent: August 19, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Richard L. Weinshank, Laurence A. Borden, Paul R. Hartig
-
Patent number: 5652113Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptor, an isolated protein which is a human 5-HT.sub.1F receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1F receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1F receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1F receptor, pharmaceutical compounds related to human 5-HT.sub.1F receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1F receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1F receptor.Type: GrantFiled: March 22, 1994Date of Patent: July 29, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Patent number: 5639652Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptor, an isolated protein which is a human 5-HT.sub.1F receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1F receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1F receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1F receptor, pharmaceutical compounds related to human 5-HT.sub.1F receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1F receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1F receptor.Type: GrantFiled: August 22, 1994Date of Patent: June 17, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Patent number: 5610174Abstract: The present invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the following structure: ##STR1## wherein each of the substiutents for the compound is as defined in the specification.Type: GrantFiled: June 2, 1995Date of Patent: March 11, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Douglas A. Craig, Carlos C. Forray, Charles Gluchowski, Theresa A. Branchek
-
Patent number: 5602024Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y5 receptor, an isolated protein which is a human Y5 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y5 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y5 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y5 receptor, pharmaceutical compounds related to human Y5 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y5 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y5 receptor.Type: GrantFiled: December 2, 1994Date of Patent: February 11, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
-
Patent number: 5595880Abstract: The present invention provides an isolated nucleic acid molecule encoding an .alpha..sub.2B -adrenergic receptor, and an isolated protein which is a human .alpha..sub.2B -adrenergic receptor. The invention also provides vectors comprising DNA molecules encoding a human .alpha..sub.2B -adrenergic receptor, and vectors adapted for expression of the .alpha.2b.sub.2B -adrenergic receptor in bacterial, yeast, or mammalian cells. In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the .alpha.2b.sub.2B -adrenergic receptor, a method for determining whether a ligand which is not known to be capable of binding to the .alpha.2b.sub.2B -adrenergic receptor can bind to the .alpha..sub.2B -adrenergic receptor on the surface of a cell, and a method of screening drugs to identify drugs to identify drugs which specifically interact with, and bind to, the .alpha..sub.2B -adrenergic receptor. The invention herein also concern an antibody directed to the human .alpha..sub.Type: GrantFiled: October 22, 1992Date of Patent: January 21, 1997Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Paul R. Hartig